All In Biotech

Drug Trial Radar · NCT00751881

An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis

A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,169

Actual

Start

Aug 2008

Primary completion

Apr 2012

Study completion Aug 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Sep 12, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS. Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression. Other secondary objectives were: * To assess the effect of the two doses of teriflunomide in comparison to placebo on: * Fatigue; * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being. * To evaluate the safety and tolerability of teriflunomide.

Conditions

  • Multiple Sclerosis

Interventions

  • PlaceboDrug

    Film-coated tablet Oral administration

  • TeriflunomideDrug

    Film-coated tablet Oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Core Treatment Period: Annualized Relapse Rate (ARR): Poisson Regression EstimateTime frame: Core treatment period between 48 - 152 weeks depending on time of enrollment

Locations

193 sites in 26 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Investigational Site Number 840041

    Phoenix, Arizona

  • Sanofi-Aventis Investigational Site Number 840084

    Tucson, Arizona

  • Sanofi-Aventis Investigational Site Number 840008

    Loma Linda, California

  • Sanofi-Aventis Investigational Site Number 840034

    Modesto, California

  • Sanofi-Aventis Investigational Site Number 840090

    Fort Collins, Colorado

  • Sanofi-Aventis Investigational Site Number 840011

    Fairfield, Connecticut

  • Sanofi-Aventis Investigational Site Number 840013

    Maitland, Florida

  • Sanofi-Aventis Investigational Site Number 840083

    Ocala, Florida

  • Sanofi-Aventis Investigational Site Number 840086

    Ormond Beach, Florida

  • Sanofi-Aventis Investigational Site Number 840025

    Sarasota, Florida

  • Sanofi-Aventis Investigational Site Number 840015

    St. Petersburg, Florida

  • Sanofi-Aventis Investigational Site Number 840033

    Sunrise, Florida

  • Sanofi-Aventis Investigational Site Number 840063

    Elk Grove Village, Illinois

  • Sanofi-Aventis Investigational Site Number 840064

    Flossmoor, Illinois

  • Sanofi-Aventis Investigational Site Number 840039

    Fort Wayne, Indiana

  • Sanofi-Aventis Investigational Site Number 840012

    Indianapolis, Indiana

  • Sanofi-Aventis Investigational Site Number 840016

    Des Moines, Iowa

  • Sanofi-Aventis Investigational Site Number 840069

    Clinton Township, Michigan

  • Sanofi-Aventis Investigational Site Number 840075

    Grand Rapids, Michigan

  • Sanofi-Aventis Investigational Site Number 840061

    Traverse City, Michigan

  • Sanofi-Aventis Investigational Site Number 840076

    Minneapolis, Minnesota

  • Sanofi-Aventis Investigational Site Number 840079

    Tupelo, Mississippi

  • Sanofi-Aventis Investigational Site Number 840088

    St Louis, Missouri

  • Sanofi-Aventis Investigational Site Number 840060

    Syracuse, New York

  • Sanofi-Aventis Investigational Site Number 840029

    Charlotte, North Carolina

  • Sanofi-Aventis Investigational Site Number 840074

    Bismarck, North Dakota

  • Sanofi-Aventis Investigational Site Number 840026

    Cincinnati, Ohio

  • Sanofi-Aventis Investigational Site Number 840078

    Dayton, Ohio

  • Sanofi-Aventis Investigational Site Number 840066

    Tulsa, Oklahoma

  • Sanofi-Aventis Investigational Site Number 840024

    Portland, Oregon

  • Sanofi-Aventis Investigational Site Number 840073

    Philadelphia, Pennsylvania

  • Sanofi-Aventis Investigational Site Number 840022

    Philadelphia, Pennsylvania

  • Sanofi-Aventis Investigational Site Number 840068

    Greenville, South Carolina

  • Sanofi-Aventis Investigational Site Number 840071

    Cordova, Tennessee

  • Sanofi-Aventis Investigational Site Number 840036

    Nashville, Tennessee

  • Sanofi-Aventis Investigational Site Number 840007

    San Antonio, Texas

  • Sanofi-Aventis Investigational Site Number 840006

    Bennington, Vermont

  • Sanofi-Aventis Investigational Site Number 840089

    Seattle, Washington

  • Sanofi-Aventis Investigational Site Number 840020

    Charleston, West Virginia

  • Sanofi-Aventis Investigational Site Number 036005

    Bedford Park, Australia

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.